

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Felix Eckstein
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eurostars-2 program	Research grant (grant ID: E! 114932)
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Merck KGA	Chondrometrics
		Kolon Tissuegene	Chondrometrics
		Galapagos	Chondrometrics
		Novartis	Chondrometrics
		EU Horizon 2020	Research grant (PROTO, grant agreement 101095635)
3	Royalties or licenses	None	
4	Consulting fees	Merck KGA	me

		Kolon Tissuegene	me
		Galapagos	me
		Novartis	me
		4P Pharma	me
		Formation Bio	me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Galapagos 4P Pharma Formation Bio	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Chondrometrics GmbH	Co-owner
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	Chondrometrics GmbH	Employment

Please summarize the above conflict of interest in the following box:

The author is an employee and co-owners of Chondrometrics GmbH. He has received grants or contracts from Merck KGA, Kolon Tissuegene, Galapagos, Novartis, and the European Union (EU). He has provided consulting services to Merck KGA, Kolon Tissue Gene, Galapagos, Novartis, 4P Pharma, and Formation Bio. He has participated in Data Safety Monitoring Boards of Galapagos, 4P Pharma and Formation Bio.

Please place an "X" next to the following statement to indicate your agreement:

X / I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024

Your Name: Nicholas Brisson

Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES

Manuscript number (if known): 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Research Foundation (DFG - Deutsche Forschungsgemeinschaft)	I have received research funding from the German Research Foundation (Projects #BR 6698/1-1 & DU 298/25-1).
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Horizon Europe Framework Programme (HORIZON)	I have received research funding from the European Union under Grant Agreement Nr. 101095635 (PROTO).
3	Royalties or licenses	___None	

4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	<i>OAC Open</i>	I have received honoraria for my role as Associate Editor for <i>OAC Open</i> .

Please summarize the above conflict of interest in the following box:

The author has received grants from the German Research Foundation and the European Union. He has also received honoraria in his role as Associate Editor for *OAC Open*.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Susanne Maschek
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Chondrometrics GmbH	Co-owner
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	Chondrometrics GmbH	Employment

The author is an employee and co-owner of Chondrometrics GmbH

Please place an "X" next to the following statement to indicate your agreement:

X / I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Felix Eckstein
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	Chondrometrics GmbH	Employment

The author is an employee of Chondrometrics GmbH

Please place an "X" next to the following statement to indicate your agreement:

X / I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Francis Berenbaum
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	4P Parma, Grunenthal, GSK, Eli Lilly, Heel, Astra	

		Zenneca, Diffusion Rx, Nordic Bioscience, Novartis, Pfizer, Servier, Zoetis	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Viartis, Pfizer	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Nordic Pharma	
8	Patents planned, issued or pending	4Moving Biotech	
9	Participation on a Data Safety Monitoring Board or Advisory Board	AstraZeneca, Sun Pharma, Nordic Bioscience	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	4P Pharma 4Moving Biotech	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

The author has received consulting fees from 4P Pharma, Grunenthal, GSK, Eli Lilly, Heel, AstraZeneca, Diffusion Rx, Nordic Bioscience, Novartis, Pfizer, Servier, Zoetis, and Viartis. He has participated in data safety monitoring boards of AstraZeneca, Sun Pharma and Nordic Bioscience. He owns stocks or stock options of 4P Pharma and 4Moving Biotech.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Georg Duda
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	EU Grant	Charité and BIH
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

The author has received funding from the European Union.

Please place an "X" next to the following statement to indicate your agreement:

X / I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: May 2, 2024
Your Name: Wolfgang Wirth
Manuscript Title: CLINICAL VALIDATION OF FULLY AUTOMATED LAMINAR KNEE CARTILAGE TRANSVERSE RELAXATION TIME (T2) ANALYSIS IN ACL-INJURED KNEES
Manuscript number: 24-194

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eurostars-2 program	Research grant (grant ID: E! 114932)
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	EU Horizon 2020	Research grant (PROTO, grant agreement 101095635)
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Chondrometrics GmbH	Share-holder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	Chondrometrics GmbH	Employment

The author is an employee and co-owner of Chondrometrics GmbH

Please place an "X" next to the following statement to indicate your agreement:

X / I certify that I have answered every question and have not altered the wording of any of the questions on this form.